Company Overview

Revvity, Inc. (formerly PerkinElmer, Inc.) provides health sciences solutions, technologies, and services globally. Founded in 1937 and headquartered in Waltham, Massachusetts, the company rebranded to Revvity in April 2023. Revvity is a leading provider offering complete workflows from discovery to development, and diagnosis to cure, serving diverse markets within the healthcare and life sciences sectors.

Business Segments

Revvity operates through two primary business segments:

Life Sciences Segment

This segment supplies instruments, reagents, informatics, software, subscriptions, detection and imaging technologies, warranties, training, and DNA sequencing services. It primarily caters to pharmaceutical and biotechnology companies, academic research institutions, and government laboratories.

Diagnostics Segment

This segment provides instruments, reagents, assay platforms, and software products essential for the early detection of genetic disorders (especially in pregnancy and early childhood) and infectious disease testing. Its products are crucial for testing and screening genetic abnormalities, disorders, and diseases such as Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions.

Key Products and Technologies

Revvity offers a comprehensive suite of instruments, tests, services, and software solutions for the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company develops technologies that enable and support genomic workflows. These include:

- Genomic Workflows: Utilizing protein coupled receptor and next-generation DNA sequencing for applications in oncology, newborn screening for rare genetic conditions, immunodiagnostics, and drug discovery.

- Key Brands & Platforms: AutoDELFIA, DELFIA, DELFIA Xpress, EUROIMMUN, EUROArray, JANUS, MultiPROBE, Sciclone, LabChip, VICTOR2D, and T-SPOT.

Target Markets and Customers

Revvity serves a broad range of clients globally, including:

- Pharmaceutical and biotechnology companies

- Laboratories (clinical, research, and diagnostic)

- Academic and research institutions

- Public health authorities

- Private healthcare organizations

- Physicians and healthcare providers

- Government agencies

Recent Financial Performance

Q2 2025 Results (ended June 29, 2025)

- Revenue: $720 million (4% reported growth; 3% organic growth)

- GAAP EPS: $0.46

- Adjusted EPS (continuing operations): $1.18

Q1 2025 Results (ended March 30, 2025)

- Revenue: $665 million (2% reported growth; 4% organic growth)

- GAAP EPS: $0.35

- Adjusted EPS (continuing operations): $1.01

Full Year 2024 Performance

- Revenue: $2.76 billion (0.16% increase from $2.75 billion in 2023)

- Earnings: $270.39 million (-60.99% decrease)

Current Business Developments

Strategic Partnerships

- Genomics England Alliance: Expanded collaboration to provide DNA sequencing services for newborn screening for rare genetic conditions. This initiative includes an integrated end-to-end solution and a localized lab, aiming to screen 100,000 newborns and reinforcing Revvity's leadership in this field.

Product Approvals

- FDA Approval for T-SPOT TB Test Automation: Secured FDA approval for a more automated platform integrated with its T-SPOT latent tuberculosis test. This launch enhances laboratory productivity and allows for faster, high-throughput diagnostic results, particularly vital in the US market.

Software Business Growth

- Signals Software: The Signals Software business, accounting for approximately 8% of total revenue, demonstrated robust performance with organic growth exceeding 20% in Q1 2025 and stronger growth projected for Q2. The franchise achieved approximately 30% growth and set a new record for quarterly orders in Q2 2025.

Market Challenges and Outlook

- Diagnostics Segment Challenges: The Diagnostics segment experienced headwinds in China due to changes in hospital lab reimbursement policies, impacting the Immunodiagnostics business.

- Revised Outlook: Revvity Inc lowered its full-year organic growth outlook to 2% to 4% (a 1% decrease from prior expectations).

2025 Financial Guidance (as of Q1 2025 results)

- Revenue Guidance: Raised to $2.83 - $2.87 billion (reflecting foreign currency exchange rate changes).

- Organic Growth Rate: Projected to remain between 3% and 5%.

Capital Allocation Strategy

Revvity Inc actively manages its capital through share repurchases and free cash flow generation.

- Share Repurchases: Repurchased nearly $300 million worth of stock in Q2 2025, bringing total repurchases to nearly $450 million for the first half of the year.

- Free Cash Flow: Generated $115 million in free cash flow during Q2 2025, maintaining a solid 90% conversion rate year-to-date.

The company is focused on delivering comprehensive health sciences solutions while strategically investing in growth areas such as genomics, diagnostic automation, and software platforms. Revvity remains committed to adapting to the evolving macroeconomic landscape, leveraging its strengths to drive continued growth and innovation in the health science sector.